🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT03349762
Recruiting Observational

Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery

NCT03349762 · tracked via the Priya Life Science China tracker
Sponsor
Xi Shan Wang
Phase
Observational
Started
2018-11-02
Last updated
2024-06-03

Condition(s) studied

Colorectal Cancer

Study summary

To evaluate the efficacy and safety of Huaier granules for Prevention of Recurrence and Metastasis of colorectal cancer patients following radical surgery

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Males or females ages 18-75 years; 2. The first time to the therapy of patients who received the radical surgery within two months, Postoperative histopathology confirms the diagnosis of colorectal cancer with stage IIB, IIC and III ( TNM classification) 3. ECOG score of 0-2; 4. No history of malignant tumors; 5. The patients are volunteered for the study, sign informed consent form and cooperate with Investigator to collect data. Exclusion Criteria: 1. Patients have basic diseases including heart diseases, cerebrovascular disease, lung disease, severe hypertension or diabetes with poor glycemic control; 2. confirmed infections after surgery ; 3. Patients who have post-surgery complications or who are currently under the influence of the radical surgery for colorectal cancer; 4. Being infected with syphilis or with other blood-borne infectious diseases; 5. Pregnancy or lactation; or women of childbearing potential not using contraception; 6. Patients who have taken Traditional Chinese Medicines with efficacy and indications similar to that of Huaier granule - including, but not limited to, compound Banmao capsule., Huachansu capsule, Kangai Injection and Pingxiao tablets; 7. Patients who are suffering from mental illness or Conditions that are considered not suitable for this study investigators.

Primary outcome measure(s)

Trial sites (22)

FacilityCityRegionStatus
The Fourth Hospital of Hebei Medical University Shijiazhuang Hebei Recruiting
The First Clinical Hospital affiliated to Harbin Medical University Harbin Heilongjiang Recruiting
The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang Recruiting
Hubei Cancer Hospita Wuhan Hubei Recruiting
Union Hospital Tongji College Huazhong University of Science and Technology Wuhan Hubei Recruiting
Hunan Provincial People's Hospital Changsha Hunan Recruiting
Xiangya Hospital Central South University Changsha Hunan Recruiting
Changzhou No.2 People's Hospital Changzhou Jiangsu Recruiting
The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu Recruiting
Northern Jiangsu People's Hospital Yangzhou Jiangsu Recruiting
Anshan Cancer Hospital Anshan Liaoning Recruiting
Ansteel Group General Hospital Anshan Liaoning Recruiting
The First Affiliated Hospital of Jinzhou Medical University Jinzhou Liaoning Recruiting
Shandong Provincial Hospital Jinan Shandong Recruiting
The Affiliated Hospital of Qingdao University Qingdao Shandong Recruiting
Yantai Yuhuangding Hospital Yantai Shandong Recruiting
Zaozhuang Municipal Hospital Zaozhuang Shandong Recruiting
First Affiliated Hospital of Xi'an Jiaotong University Xi’an Shanxi Recruiting
Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin Municipality Recruiting
First Affiliated Hospital of Xinjiang Medical University Ürümqi Xinjiang Recruiting
Cancer Hospital Chinese Academy of Medical Sciences Beijing China Recruiting
Fudan University Shanghai Cancer Center Shanghai China Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03349762 on ClinicalTrials.gov ↗ ← All trials in China